RT Journal Article
SR Electronic
T1 Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: an observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.09.21258271
DO 10.1101/2021.06.09.21258271
A1 Verschelden, Gil
A1 Noeparast, Maxim
A1 Noparast, Maryam
A1 Lauwers, Maïlis
A1 Michel, Charlotte
A1 Cotton, Frédéric
A1 Goyvaerts, Cleo
A1 Hites, Maya
YR 2021
UL http://medrxiv.org/content/early/2021/07/26/2021.06.09.21258271.abstract
AB Deficiency of the element zinc is associated with cytokine releasing syndrome (CRS) and the related acute respiratory distress syndrome as well as impaired antiviral response. Similar complications associate with severe SARS-CoV-2.We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hopital Erasme, Brussels) to address the zinc status, the association between the plasma zinc concentration, development of CRS, and the clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients. One hundred and thirty-nine eligible patients were included between May 2020 and November 2020 (median age of 65 years [IQR, 54 to 77]).Our cohort’s mean plasma zinc concentration was 56.2 µg/dL (standard deviation [SD], 14.8) compared to 75.7 µg/dL (SD = 18.9 µg/dL) in the retrospective non-COVID-19 control group (N = 1513; P <.001). Markedly, the absolute majority of patients (96%) were zinc deficient (<80 µg/dL).The mean zinc concentration was lower in patients with CRS compared to those without CRS (−5 µg/dL; 95% CI, -10.5 to 0.051; P = 0.048).Among the tested outcomes, zinc concentration is significantly correlated with only the length of hospital stay (rho = -0.19; P = 0.022), but not with mortality or morbidity. As such, our findings do not support the role of zinc as a robust prognostic marker among hospitalized COVID-19 patients who in our cohort presented high prevalence of zinc deficiency. It might be more beneficial to explore the role of zinc as a biomarker for assessing the risk of developing a tissue-damaging CRS and predicting outcomes in patients diagnosed with COVID-19 at the early stage of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFonds Wetenschappelijk Onderzoek (FWO) VlaanderenAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved on 8 May 2020 by the IRB of CUB Hopital Erasme, Route de Lennik 808, 1070, Anderlecht, BruxellesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, (Gil Verschelden).ARDSAcute respiratory distress syndromeAUROCArea under the receiver operating characteristic curveBMIBody mass indexcHISCOVID-19-associated hyperinflammatory syndromeCIConfidence intervalCRSCytokine release syndromeICUIntensive care unitIQRInterquartile rangeSARS-CoV-2severe acute respiratory syndrome coronavirus 2SDStandard deviation